Our portfolio company Sirius Medical secures growth funding from new and existing investors to further develop the Sirius Pintuition portfolio and expand international sales

Eindhoven, 4th of February 2025 – Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day. This investment round was led by Invest-NL and Nextgen Ventures, with support from De Groot Family Office and existing investors Brabant Development Agency (BOM), Holland Capital, Curie Capital, Team Holmium, and Sirius Medical’s team.

World Cancer Day is a poignant reminder of the ongoing fight against cancer, and this milestone reflects Sirius Medical’s commitment to enhancing cancer care. Praised by breast cancer surgeons worldwide, the Sirius Pintuition® surgical navigation platform enables simple, best-in-class wire-free localization for breast-conserving surgery in any hospital. This latest funding round empowers Sirius Medical to enhance the Sirius Pintuition system and GPSDetect™ software platform, focusing on usability and intuitiveness, and extending its applications. Additionally, the investment will substantially bolster the sales infrastructure and support expansion into new markets.

“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally,” says Bram Schermers, CEO of Sirius Medical. “This funding round, in the current fundraising environment, is a clear testament to the talent of the Sirius Medical team, and the Pintuition technology that we have developed. We are proud to continue contributing to the fight against cancer and look forward to the next phase of growth for Sirius Medical. We will have more exciting news to announce soon.”

“From Holland Capital, we have been supporting Sirius Medical for many years to bridge the notorious ‘valley of death,’” said Jan Frens van Giessel, partner at Holland Capital. “Many young companies in medical technology fail due to a lack of funding, as reported by Financieele Dagblad a few weeks ago. For investors, investing in medical technology is risky because the development and sales processes are complex, uncertain, and lengthy. We experience this at Holland Capital as well, but when a company manages to distinguish itself and achieves key technical and commercial milestones, we do everything we can to arrange financing. This is also the case with Sirius Medical.”

“We have seen Sirius Medical grow over the years into a successful med-tech scale-up, with sales in the US, UK, almost all EU countries, and Australia. We are proud of the impressive results the Sirius Medical team has achieved. We welcome the new investors, NextGen and InvestNL, so that together we can make this Dutch healthcare innovation available to women with breast cancer worldwide,” said Jan Frens van Giessel, partner at Holland Capital.

About World Cancer Day 

World Cancer Day, observed on February 4th, is a global initiative to raise awareness, inspire action, and work together to reduce the impact of cancer worldwide.

About Sirius Medical 

With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. Sirius Pintuition is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 250 centers and 35.000 procedures globally.

Holland Venture wins M&A ‘Best Small Cap Deal’ award

Amsterdam, 14 December 2018 - Yesterday the annual ceremony of the M & A awards took place in the Beurs van Berlage in Amsterdam. Holland Venture was nominated for two awards: 'Best Venture & Growth Capital Provider' and 'Best Small Cap Deal'.  Holland...

Holland Venture wint M&A ‘Best Small Cap Deal’ award

Amsterdam, 14 december 2018 - Gister vond de jaarlijkse uitreiking van de M&A awards plaats in de Beurs van Berlage in Amsterdam. Holland Venture ging naar de uitreiking met twee nominaties op zak. Te weten ‘Best Venture & Growth Capital Provider’ en ‘Best...

Highcare supports management buy-out Zorgzuster

Roosendaal/Maastricht, 27 November 2018 – Highcare and Ralph Smeets acquire all shares of Zorgzuster Nederland from Start People (part of USG People The Netherlands). Ralph Smeets has founded Zorgzuster in 2010. Highcare is the employment and deployment agency in the...

Highcare ondersteunt management buy-out zorgzuster

Roosendaal/Maastricht, 27 november 2018 - Highcare en Ralph Smeets, nemen alle aandelen in Zorgzuster Nederland over van Start People (onderdeel van USG People The Netherlands). Ralph Smeets heeft in 2010 Zorgzuster opgericht. Highcare is het uitzend- en...

Holland Venture invests in WSO2 integrator Yenlo

Amsterdam, 19 November 2018 – Private Equity firm Holland Venture invests in Yenlo, the leading integration specialist on WSO2 open source middleware technology. The management and shareholders have set a target for the coming years to strengthen the growth of the...

Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411

 

Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120

Contact
info@hollandcapital.nl